Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System
Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation ...
CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial
CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to ...
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
How Can Clinical Trials Improve Diversity? CTM’s Cara Brant Explains
Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...
manilatimes1d
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m 2 dose associated with 20% increase in IL-12 levels compared to 79mg/m 2 dose. Results from OVATION 2 Study continue ...
The American Journal of Managed Care2d
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...
Aptose's leukemia drug cleared to double clinical trial dose
Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, reports dose-escalation approval for tuspetinib, ...
IN8bio reports promising phase 1 results for leukemia therapy
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
pharmaphorum6d
Merck KGaA's ATR cancer drug cleared for further trials after phase 1 trial success
Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. Short for ataxia telangiectasia and Rad3-related ...